| Mass Balance Study of [14C]Chiauranib (NCT05371899) | Chipscreen Biosciences, Ltd. | 2022-07-20 |
| Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer (NCT05450965) | University of Maryland, Baltimore | 2022-07-19 |
| Tempus Small Cell Lung Cancer Observational Study (Sculptor) (NCT05257551) | Tempus AI | 2022-07-13 |
| Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer (NCT04952480) | AHS Cancer Control Alberta | 2022-06-13 |
| A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain (NCT05419076) | Memorial Sloan Kettering Cancer Center | 2022-06-10 |
| To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT05253053) | TransThera Sciences (Nanjing), Inc. | 2022-04-13 |
| RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (NCT05285033) | Intergroupe Francophone de Cancerologie Thoracique | 2022-04-01 |
| A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China (NCT05337163) | Creative Biosciences (Guangzhou) Co., Ltd. | 2022-02-25 |
| Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer (NCT05223647) | Norwegian University of Science and Technology | 2022-01-11 |
| Association of Thoraco-mediastinal Radiotherapy With Maintenance Immunotherapy Treatment With Atezolizumab (NCT06771518) | Regina Elena Cancer Institute | 2021-12-15 |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT05027867) | Kartos Therapeutics, Inc. | 2021-12-06 |
| DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS (NCT05254119) | Mahmut Gumus | 2021-12-01 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (NCT05091567) | Hoffmann-La Roche | 2021-11-18 |
| Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy (NCT04985201) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-11-01 |
| Circulating EV Long RNA Profiles in SCLC (NCT05191849) | Fudan University | 2021-10-25 |
| AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC) (NCT04885998) | Amgen | 2021-09-27 |
| Liver Directed RT + Chemo-immunotherapy for ES-SCLC (NCT04923776) | Brian Henick, MD | 2021-09-20 |
| An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese (NCT05245994) | Li Zhang, MD | 2021-08-21 |
| Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy (NCT04698941) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-07-25 |
| Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99) (NCT04924101) | Merck Sharp & Dohme LLC | 2021-07-15 |
| A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer (NCT04951115) | Weill Medical College of Cornell University | 2021-07-12 |
| A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors (NCT04841538) | Elpiscience Biopharma, Ltd. | 2021-07-01 |
| A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (NCT04870112) | AstraZeneca | 2021-06-28 |
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). (NCT04472949) | Swiss Cancer Institute | 2021-06-25 |
| A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD) (NCT04834778) | HiberCell, Inc. | 2021-06-08 |
| Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer (NCT04590781) | Xencor, Inc. | 2021-05-10 |
| Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer (NCT04782089) | Qilu Hospital of Shandong University | 2021-05-06 |
| Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer (NCT04542369) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-05-01 |
| Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC (NCT04683198) | Chinese Academy of Medical Sciences | 2021-04-01 |
| Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer (NCT05761977) | Hellenic Cooperative Oncology Group | 2021-03-31 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (NCT04272034) | Incyte Corporation | 2021-03-26 |
| Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors (NCT04742959) | TransThera Sciences (Nanjing), Inc. | 2021-03-14 |
| Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors (NCT04579757) | Hutchmed | 2021-03-05 |
| TH1902 in Patients With Advanced Solid Tumors (NCT04706962) | Theratechnologies | 2021-03-04 |
| Effect of Combination Therapy on SCLC After Initial Treatment Failure (NCT04790955) | First Affiliated Hospital of Harbin Medical University | 2021-03-01 |
| Study of AZD2811 + Durvalumab in ES-SCLC (NCT04745689) | AstraZeneca | 2021-02-23 |
| Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC (NCT04920981) | Intergroupe Francophone de Cancerologie Thoracique | 2021-02-02 |
| Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy (NCT05552846) | Ruijin Hospital | 2021-01-30 |
| Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy (NCT05001971) | Hunan Cancer Hospital | 2021-01-30 |
| The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. (NCT04691063) | Jiangsu HengRui Medicine Co., Ltd. | 2021-01-22 |
| Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases (NCT04610684) | Jeffrey Clarke | 2021-01-05 |
| Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients (NCT04696939) | Shanghai Pulmonary Hospital, Shanghai, China | 2021-01-01 |
| A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-12-14 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (NCT04624204) | Merck Sharp & Dohme LLC | 2020-12-08 |
| Study of LP002 in Combination With Chemotherapy for Patients With Extensive Stage Small Cell Lung Cancer (NCT04740021) | Taizhou HoudeAoke Biomedical Co., Ltd. | 2020-12-02 |
| Immune Checkpoint Inhibition With Lurbinectedin Relapsed/Recurrent SCLC (NCT04610658) | H. Lee Moffitt Cancer Center and Research Institute | 2020-11-23 |
| TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy (NCT04596033) | Genocea Biosciences, Inc. | 2020-11-11 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (NCT04585750) | PMV Pharmaceuticals, Inc | 2020-10-29 |
| Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors (NCT04640480) | SN BioScience | 2020-10-21 |
| A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer (NCT04890795) | Advenchen Laboratories Nanjing Ltd. | 2020-10-19 |
| Talazoparib and Thoracic RT for ES-SCLC (NCT04170946) | University Health Network, Toronto | 2020-10-05 |
| A Study of Gimatecan (ST1481) in Small Cell Lung Cancer (NCT04501029) | Lee's Pharmaceutical Limited | 2020-10-01 |
| Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer (NCT04381910) | Luye Pharma Group Ltd. | 2020-09-28 |
| A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC). (NCT04422210) | Hoffmann-La Roche | 2020-09-22 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (NCT04140526) | OncoC4, Inc. | 2020-09-16 |
| PF-07104091 as a Single Agent and in Combination Therapy (NCT04553133) | Pfizer | 2020-09-16 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors (NCT04242199) | Incyte Corporation | 2020-09-04 |
| PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer (NCT04539977) | Shanghai Pulmonary Hospital, Shanghai, China | 2020-09-01 |
| Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer (NCT04210037) | Ascentage Pharma Group Inc. | 2020-08-20 |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours (NCT04504669) | AstraZeneca | 2020-08-18 |
| IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer (NCT04434482) | Impact Therapeutics, Inc. | 2020-08-07 |
| The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance (NCT04450043) | Massachusetts General Hospital | 2020-08-01 |
| Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. (NCT04490421) | Fuzhou General Hospital | 2020-08-01 |
| A Real-world Study of Durvalumab for Lung Cancer in China (NCT04672759) | Peking Union Medical College Hospital | 2020-07-28 |
| eRAPID: Online Symptom Reporting in Lung Cancer (NCT04324437) | University of Leeds | 2020-07-20 |
| A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First-Line Chemotherapy (NCT04352413) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2020-06-18 |
| Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (NCT04361825) | Se-Hoon Lee | 2020-06-17 |
| A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer (NCT04400188) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-11 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT04332653) | NeoImmuneTech | 2020-06-10 |
| PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers (NCT04209595) | National Cancer Institute (NCI) | 2020-04-08 |
| Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer (NCT04342429) | Emory University | 2020-03-19 |
| Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (NCT04152499) | Klus Pharma Inc. | 2020-02-28 |
| A Multicenter Cancer Biospecimen Collection Study (NCT04510129) | Cofactor Genomics, Inc. | 2020-02-05 |
| A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer (NCT04256421) | Hoffmann-La Roche | 2020-02-04 |
| A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors (NCT04247126) | Syros Pharmaceuticals | 2020-01-23 |
| Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC (NCT04010357) | Case Comprehensive Cancer Center | 2020-01-13 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis (NCT04187872) | University of Florida | 2020-01-10 |
| Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer (NCT04173325) | Augusta University | 2020-01-06 |
| PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 (NCT04199741) | Memorial Sloan Kettering Cancer Center | 2019-12-11 |
| Closed vs. Open Face Masks for Cranial Radiotherapy (NCT04079595) | University of Zurich | 2019-12-09 |
| Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors (NCT04116320) | Craig L Slingluff, Jr | 2019-11-21 |
| Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis (NCT04171986) | Tianjin Medical University Cancer Institute and Hospital | 2019-11-10 |
| Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers (NCT06255197) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2019-11-04 |
| Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer (NCT04073550) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-10-31 |
| Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (NCT04165330) | Sarcoma Oncology Research Center, LLC | 2019-10-17 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (NCT04032704) | Seagen Inc. | 2019-10-09 |
| Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer (NCT04128800) | Tianjin Medical University Cancer Institute and Hospital | 2019-10-01 |
| CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) (NCT03904719) | AnewPharma | 2019-09-18 |
| A Study of SHR-1316 and Fluzoparib（SHR-3162） in Small Cell Lung Cancer Patients (NCT04041011) | Jiangsu HengRui Medicine Co., Ltd. | 2019-09-17 |
| Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma (NCT03958045) | Zhonglin Hao | 2019-09-04 |
| A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) (NCT04022876) | Aileron Therapeutics, Inc. | 2019-09-03 |
| Watchful Observation of Patients With LD-SCLC Instead of the PCI (NCT04168281) | Sergiusz Nawrocki | 2019-09-02 |
| Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC (NCT03994744) | Hunan Cancer Hospital | 2019-08-20 |
| Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain (NCT03488472) | Drexell Hunter Boggs | 2019-08-09 |
| Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma (NCT03467360) | Centre Antoine Lacassagne | 2019-08-02 |
| Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer (NCT04012606) | Shanghai Junshi Bioscience Co., Ltd. | 2019-07-23 |
| Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (NCT04005716) | BeiGene | 2019-07-22 |
| A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer (NCT03898791) | Eli Lilly and Company | 2019-07-16 |
| PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study (NCT04535739) | Chinese Academy of Medical Sciences | 2019-07-01 |